Quest Diagnostics and Hologic have entered into a strategic alliance to more broadly offer testing based on Hologic’s Aptima family of products, as well as to co-develop and promote advanced diagnostic solutions to improve women’s health.
Under a nonexclusive agreement with an initial five-year term, the companies will focus on clinical areas critical to women’s health. Quest will transition to a broader offering of services based on Hologic’s Aptima products, which include FDA-approved or -cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea, and Trichomonas vaginalis. Quest will continue to use Hologic’s ThinPrep liquid-based cytology products.
The companies will implement joint programs to advance women’s health issues with medical associations and patient advocacy groups and to sponsor research. Financial terms of the collaboration were not disclosed.
Quest Diagnostics, 800-445-0185